Afaxys and Exeltis Renew Partnership to Expand Access to Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System

CHARLESTON, S.C., June 30, 2025 /PRNewswire/ -- Afaxys, Inc., a Public Benefit Corporation and first-of-its kind socially conscious healthcare company focused on serving public health professionals and their patients, today announced the renewal of its alliance to support access to Twirla^® (levonorgestrel and ethinyl estradiol) transdermal system, and additional Exeltis products, in the public health market. The renewal follows the August 2024 acquisition of Agile Therapeutics by Insud Pharma, the parent company of Exeltis USA, with whom Afaxys has partnered since 2022.

The renewed partnership between Afaxys and Exeltis underscores both organizations' ongoing commitment to expanding access to innovative contraceptive options within the U.S. public health market, like Twirla, a low-dose, non-daily contraceptive patch.

"Our partnership with Exeltis reflects our shared vision to ensure that women have consistent access to high-quality, affordable contraceptive options that fit their lifestyles," said Ronda Dean, CEO & Co-Founder of Afaxys. "Together with Afaxys, we're making it easier for women to access Twirla—when and where they need it," added Eduardo Fernandez, EVP of Corporate Development at Exeltis USA.

The promotional alliance enables Afaxys and Exeltis to continue supporting healthcare professionals with education, resources, and expanded access to Twirla, reinforcing both companies' focus on improving reproductive health outcomes nationwide.

Christian Bloomgren, President & CCO of Afaxys, added, "Our alliance with Exeltis expands our impact across public health by broadening the range of solutions we offer to healthcare professionals and the patients they serve. The renewed partnership strengthens our combined ability to deliver innovative, affordable options that address the diverse needs of women across the country."

About Afaxys
Afaxys, a Public Benefit Corporation, uniquely partners with public health and private industry to ensure healthcare professionals have stable pricing and reliable access to the products and services they need to care for their patients.

The Afaxys enterprise comprises a family of companies that operate under three wholly owned subsidiaries: Afaxys Pharma, LLC, Afaxys Drug Development, LLC and Afaxys Group Services, LLC (AGS). Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public healthcare market. Afaxys Drug Development provides development and regulatory services of pharmaceutical products with a focus on rapid and efficient launch readiness to promote Afaxys' strategic goal of cost-conscious product commercialization. AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization. For more information, visit www.afaxys.com.

About Exeltis
Exeltis USA is part of the global pharmaceutical company Insud Pharma. Exeltis is focused on delivering innovative solutions in women's health and beyond, with a growing portfolio of prescription products designed to meet evolving patient needs.

About Insud Pharma
Insud Pharma is a pharmaceutical group with more than 45 years of history, presence in around 50 countries, 9,000 employees worldwide and 20 manufacturing plants.

Insud Pharma operates throughout the value chain of the pharmaceutical industry, offering specialized knowledge in scientific research, development, manufacturing, sale and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and pharmaceutical products of brand for the care of humans and animals and biopharmaceuticals.

Insud Pharma seeks to improve health throughout the world by providing accessible, effective, safe and quality pharmacological treatments through its different business units, with continuous investment in R&D and the latest technology.

About Twirla^®
Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated for use as a method of contraception by women of reproductive potential with a body mass index (BMI) < 30 kg/m² for whom a combined hormonal contraceptive is appropriate. Healthcare providers (HCPs) are encouraged to consider Twirla's reduced efficacy in women with a BMI ≥ 25 to <30 kg/m² before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg/m². Twirla is also contraindicated in women over 35 years old who smoke.

Cigarette smoking increases the risk of serious cardiovascular events from CHC use. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.

Forward-Looking Statements
The statements in this press release that are not historical facts constitute "forward-looking statements" as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives, and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made. 

Afaxys Media Contact
Green Room Communications
[email protected] 

SOURCE Afaxys, Inc.